The significance of resections for residual masses after chemotherapy in metastatic testicular tumors

International Journal of Urology

Volumn 6, Issue 6, 1999, Pages 305-313

  Suzuki, Ken ichi ^a   Orikasa, Seiichi ^a   Hoshi, Senji ^a   Yoshikawa, Kazuyuki ^a   Saito, Seiichi ^a   Ohyama, Chikara ^a   Sato, Makoto ^a   Kawamura, Sadahumi ^a   Numahata, Kenji ^a   Ito, Akihiro ^a   Tokuyama, Satoru ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Metastatic testicular cancer; Non seminomatous germ cell tumor; Post chemotherapy surgery; Residual mass; Seminoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA; SURVIVAL RATE; TERATOMA; TESTIS CANCER;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GERMINOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENCE; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0032982411     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.00062.x     Document Type: Article

References (34)

1. 1 Einhorn LH. Treatment of testicular cancer: A new and improved model. J. Clin. Oncol. 1990; 8: 1777-81.
2. 2 Stoter G, Koopman A, Vendrik CPJ et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J. Clin. Oncol. 1989; 7: 1099-104.
3. 3 Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer 1984; 54: 2716-21.
4. 4 Levitt MD, Reynolds PM, Sheiner HJ, Byrne MJ. Non-seminomatous germ cell testicular tumors: Residual masses after chemotherapy. Br. J. Surg. 1985; 72: 19-22.
5. 5 Donohue JP, Rowland RG, Kopeeky K et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J. Urol. 1987; 137: 1176-9.
6. 6 Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J. Clin. Oncol. 1992; 10: 569-73.
7. 7 Hendry WF, A'Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br. J. Urol. 1993; 71: 208-13.
8. 8 Donohue JP, Schraffordt Koops H, Hendry WF, DeBruyne FM. Surgery in advanced disease for testicular cancer. In: Newling DWW, Jones WG (eds). EORTC Genitourinaiy group monograph 7: Prostate cancer and testicular cancer. Wiley-Liss, New York, 1990; 305-312.
9. 9 Miki T, Saki S, Kotake T. The role of salvage surgery following chemotherapy in advanced testicular cancer. Hinyokika Kiyo (Acta Urol. Jpn) 1994, 40: 951-5.
10. 10 Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J. Clin. Oncol. 1990; 8: 1683-94.
11. 11 Mostofi FK, Sobin LH. Histological typing of testis tumours. International Histological Classification of Tumours, no. 16.: World Health Organization, Geneva, 1977.
12. 12 Japanese Urological Association. The Japanese Society of Pathology (eds). General Rules for Clinical and Pathological Studies on Testicular Tumors 2nd edn. Kaneharasyuppan, Tokyo, 1997.
13. 13 Suzuki K, Orikasa S, Hoshi S et al. Surveillance study for clinical stage 1 testicular seminomas and nonseminomatous germ cell tumors. Int. J. Urol. 1998; 5: 568-74.
14. 14 Steyerberg EW, Keizer HJ, Zwartendijk J et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: A multivariate analysis. Br. J. Cancer 1993; 68: 195-200.
15. 15 Dearnaley DP, Horwich A, A'hern R et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up. Eur. J. Cancer 1991; 27: 684-91.
16. 16 Jansen RLH, Sylvester R, Sleyfer DT et al., for the EORTC GU Group. Long-term follow-up of nonseminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. Eur. J. Cancer 1991; 27: 695-8.
17. 17 Mead GM, Stenning SP, Parkinson MC et al., for the Medical Research Council Testicular Tumour Working Party. The second medical research council study of prognostic factors in nonseminomatous germ cell tumors. J. Clin. Oncol. 1992; 10: 85-94.
18. 18 Herr HW, Scheinfeld J, Pue HS et al. Surgery for a post-chemotherapy residual mass in seminoma. J. Urol. 1997; 157: 860-2.
19. 19 Newlands ES, Reynolds KW. The role of surgery in metastatic testicular germ cell tumors (GCT). Br. J. Cancer 1989; 59: 837-9.
20. 20 Steyerberg EW, Keizer SD, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J. Clin. Oncol. 1995; 13: 1177-87.
21. 21 Steyerberg EW, Donohue JP, Gerl J et al. Residual masses after chemotherapy for metastatic testicular cancer: The clinical implications of the association between retroperitoneal and pulmonary histology. Reanalysis of histology in testicular cancer study group. J. Urol. 1997; 158: 474-8.
22. 22 Matsuyama H, Yamamoto N, Sakatoku J et al. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer. Urology 1994; 44: 392-8.
23. 23 Mulders PF, Oosterhof GO, Boetes C, de Mulder PH, Theeuwes AG, Debruyne FM. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br. J. Urol. 1990; 66: 425-9.
24. 24 Tait D, Peckham MJ, Hendry WF, Goldstraw P. Postchemotherapy surgery in advanced non-seminomatous germ-cell tumours: The significance of histology with particular reference to differentiated (mature) teratoma. Br. J. Cancer 1984; 50: 601-9.
25. 25 Harding MJ, Brown IL, MacPherson SG, Turner MA, Kaye SB. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur. J. Cancer Clin. Oncol. 1989; 25: 1689-94.
26. 26 Geller ML, Bosl GJ, Chan EYW. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer 1989; 63: 440-5.
27. 27 Fox EP, Weathers TD, Williams SD et al. Outcome analysis for patients with persistent nonteratomous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. 1993; 11: 1294-9.
28. 28 Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 1982; 50: 1629-35.
29. 29 Maroto P, Tabernero JM, Villavicencio H et al. Growing teratoma syndrome: Experience of a single institution. Eur. Urol. 1997; 32: 305-9.
30. 30 Ulbright TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA. The development of non-germ malignancies within germ cell tumors: A clinicopathologic study of 11 cases. Cancer 1984; 54: 1824-33.
31. 31 Ahlgren AD, Simrell CR, Triche TJ, Ozols R, Barsky SH. Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy. Cancer 1984; 54: 2015-18.
32. 32 Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985; 56: 860--3.
33. 33 Molenaar WM, Oosterhuis JW, Meiring A, Sleyfer DT, Schrafordt Koops H, Cornelisse CJ. Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated non-seminomatous testicular tumor. Cancer 1986; 58: 264-8.
34. 34 Casted SM, de Jong B, Oosterhuis JW et al. Chromosomal changes in mature residual teratomas following polychemotherapy. Cancer Res. 1989; 49: 672-6.